[Treatment strategies for relapsed or refractory multiple myeloma: proposals for optimal treatment sequencing]
1Department of Hematology and Oncology, The University of Osaka Graduate School of Medicine.
Abstract:
The development of triple-class regimens incorporating immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies has extended progression-free survival in multiple myeloma (MM) patients. Furthermore, in recent years, novel BCMA- and GPRC5D-targeted T-cell redirection therapies, including chimeric antigen receptor (CAR) T-cell and bispecific antibody therapies, have yielded remarkable advances in MM treatment. This review discusses several factors influencing treatment efficacy and safety in this new era of immunotherapy.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

